Table 1 Baseline characteristics
N =146 | |
---|---|
Age (years) (±SD) | 34 (9) |
BMI (kg cm−2) (±SD) | 25 (5) |
Seminoma n (%) | 37/146 (25%) |
Non-seminoma n (%) | 108/146 (74%) |
Unknown n (%) | 1/146 (<1%) |
Clinical stage | |
Stadium II n (%) | 61/146 (42%) |
Stadium III n (%) | 85/146 (58%) |
IGCCCG risk groups | |
Good risk n (%) | 97/146 (66%) |
Intermediate risk n (%) | 26/146 (18%) |
Poor risk n (%) | 23/146 (16%) |
Site of metastases | |
Retroperitoneal lymph nodes | 134/146 (92%) |
Lung | 61/146 (42%) |
Mediastinal | 36/146 (25%) |
Neck | 18/146 (12%) |
Visceral | 11/146 (8%) |
Bone | 4/146 (3%) |
Brain | 3/146 (2%) |
Other | 9/146 (6%) |
AFP (μg l−1) (IQR) | 5.70 (2.75–143.50) |
HCG (U l−1) (IQR) | 7.70 (0.0–1021.1) |
LDH (U l−1) (IQR) | 445 (324–771) |
Haemoglobin (g l−1) (IQR) | 146 (133–157) |
Leukocytes (103 per μl) (±SD) | 7.54 (2.61) |
Thrombocytes (103 per μl) (±SD) | 289 (100) |
Neutrophils (103 per μl) (±SD) | 5.08 (2.10) |
Lymphocytes (103 per μl) (±SD) | 1.47 (0.52) |
CRP (mg l−1) (IQR) | 5.00 (1.00–20.25) |
Albumin (IQR) | 43 (39–46) |
NLR (IQR) | 3.18 (2.34–5.07) |
PLR (IQR) | 182 (133–167) |
SII (IQR) | 898 (511–1520) |